I had the opportunity to kick off my rare advocacy journey and experience my first Capitol Hill Day.

The MAGIC research team welcomes iMM to the consortium to add a cellular perspective to muscle-on-chip technologies

Long-awaited publication about the Phase 1 Open-Label Study of Omigapil in Patients With LAMA2- or COL6-Related Dystrophy now published.

We are honored to support groundbreaking discoveries related to SELENON-Related Disorders.

Explore an in-depth interview with Gustavo Dziewczapolski, Doctor in Neuropharmacology and Scientific Director of Cure CMD. Gain insights in

Cure CMD’s Scientific Director, Dr. Gustavo Dziewczapolski, provides a recap of his attendance at the 8th International Myology Congress in

We are honored to support groundbreaking discoveries in Collagen 6-Related Dystrophies (COL6-RD).

Honoring community member Simon Cantos and his legacy in the congenital muscular dystrophy community.

My rare disease advocacy journey started later in life. Like many, I had always felt too overwhelmed and unsure of how to start and was...

Cure CMD’s Advocacy Lead, Lani Knutson, provides a recap of events for Rare Disease Week on Capitol, February 25 — 29, 2024.

Like most families with a high school junior, we have begun the college discussion at our house. Higher ed is not uncharted territory for...

LAKEWOOD, CA — February 2, 2024 — Cure CMD & The Caregiver Compass team up to release a special edition caregiver guidebook for the CMD...